Physician profile
Keith A Walter
NPI 1518940220
$397,000.08
in general payments reported to CMS, 2019-2025
26 companies · $39K in 2025
The $39K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200K · 2020: $67K · 2021: $38K · 2022: $31K · 2023: $3,453 · 2024: $19K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $54K · Food and Beverage: $3,988 · Travel and Lodging: $3,377 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $54,185.62 |
| Food and Beverage | $3,988.12 |
| Travel and Lodging | $3,376.99 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $262.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $261,040.85 | 2019-2025 | Intralase Fs Femtosec Laser, Compact Intuitiv, Ifs Advanced Femtosec Laser |
| Omeros Corporation | $69,130.42 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $21,784.18 | 2019-2025 | Cequa |
| Glaukos Corporation | $17,108.78 | 2019-2025 | Idosetr, Istent Infinite |
| Rayner Intraocular Lenses Limited | $11,463.46 | 2022-2025 | Rayone Emv, Rayone Aspheric, Rayone Spheric |
| Novartis Pharmaceuticals Corporation | $5,011.30 | 2019 | |
| Horizon Therapeutics Plc | $2,043.37 | 2021 | |
| Shire North American Group INC | $1,608.17 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $1,561.18 | 2025 | Xdemvy |
| Oculus, INC. | $1,500.00 | 2019 | |
| Lensar, INC. | $1,300.00 | 2023 | Lensar Laser System |
| Staar Surgical Company | $716.21 | 2019 | |
| Eyevance Pharmaceuticals LLC | $455.56 | 2019-2021 | |
| Carl Zeiss Meditec, INC. | $427.93 | 2019 | |
| Alcon Vision LLC | $309.34 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $298.56 | 2022-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Dompe US, INC. | $283.26 | 2019-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $171.14 | 2022-2025 | Miebo, Lotemax Sm |
| Alcon Research LLC | $142.42 | 2025 | Unity |
| Kala Pharmaceuticals, INC. | $116.48 | 2022 | |
| Sight Sciences, INC. | $112.05 | 2022-2023 | Tearcare System |
| Beaver-Visitec International, INC. | $111.85 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $105.50 | 2023 | Acuvue, Mentor Siltex Round Spectrum |
| Carl Zeiss Meditec Cataract Technology INC. | $89.94 | 2019-2022 | |
| Quidel Corporation | $73.97 | 2019 | |
| Harrow Eye, LLC | $34.16 | 2025 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Walter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.